Erasca
ERASERAS · Stock Price
Historical price data
Overview
Erasca is a clinical-stage biotech singularly focused on developing therapies to 'erase' cancers driven by the RAS/MAPK pathway, which affects ~5.5 million new patients annually. The company's core strategy is built on its MAPKlamp™ platform, designed to overcome resistance by simultaneously targeting multiple nodes within the pathway. With a deep pipeline of small molecules, degraders, and bispecific antibodies, and led by a founder with a proven track record in precision oncology, Erasca aims to achieve durable pathway suppression and deliver transformative combination regimens.
Technology Platform
MAPKlamp™, a modality-agnostic platform designed to comprehensively shut down the RAS/MAPK pathway by simultaneously targeting upstream nodes (e.g., SHP2), downstream nodes (e.g., ERK), direct RAS, and adaptive escape routes.
Pipeline
10| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Naporafenib + Dacarbazine + Temozolomide + Trametinib | Advanced or Metastatic NRAS-mutant Melanoma | Phase 3 | |
| ERAS-007 + ERAS-601 | Advanced or Metastatic Solid Tumors | Phase 1/2 | |
| ERAS-007 + Encorafenib + Cetuximab + Palbociclib | Metastatic Colorectal Cancer | Phase 1/2 | |
| ERAS-007 + ERAS-601 + Gilteritinib | Acute Myeloid Leukemia | Phase 1/2 | |
| ERAS-601 + Cetuximab + Pembrolizumab | Advanced or Metastatic Solid Tumors | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Competition is intense, with major pharma (Amgen, BMS) holding first-generation KRAS G12C inhibitors and several biotechs (Revolution Medicines, BridgeBio) pursuing similar multi-node and next-generation strategies. Erasca differentiates through its integrated MAPKlamp™ platform strategy, modality diversity, and founder's proven track record in precision oncology.
Company Timeline
Founded in San Diego, United States
Series A: $64.0M
Series B: $200.0M
IPO — $200.0M